She is also currently the Advisor to the Council on Women and Girls at the White House.
She is currently an advisor to Symbiont IO, a fintech company focused on distributed ledger technology.
E.A.C. is currently an advisor to Advantagene and DNAtrix, and has equity interest in DNATrix; he has previously advised Oncorus, Merck, Tocagen, Ziopharm, StemCell and NanoTx.
Dr. Trowbridge is currently an advisor to the National Collaborative on Childhood Obesity Research (www.nccor.org), a partnership between multiple federal and private funding agencies, on built environment and childhood obesity prevention research development.
She is currently an advisor to the Draper Richards Kaplan Foundation investing in health entrepreneurs and is a member of the New England Journal of Medicine's Perspectives Advisory Board.
He is currently technical advisor at Alphabet and the founder of Schmidt Futures, which aims to advance society through technology, inspire scientific breakthroughs, and promote shared prosperity.
Matt is currently Special Advisor to the UN Special Envoy for Yemen, Senior Lecturer at the Fletcher School of Law and Diplomacy, Director of the Center for Empathy in International Affairs and an Associate Fellow at Chatham House.
From 1990 to 2005, he served as the director of CIIFAD, the Cornell International Institute for Food, Agriculture and Development, and he is currently senior advisor for the SRI-Rice center in IP/CALS and a CIPA core faculty member.
E.A.C is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., Sigilon Therepeutics and DNAtrix Inc. and has equity interest in DNAtrix; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta, Merck, Janssen, Karcinolysis, and Shanaghai Biotech.
He is currently an advisor to Appolicious.
